HuREL® Enters Into Cell-Based R&D Collaboration With Sanofi US To Validate HuRELhuman™ In Vitro Liver Tissue Co-Culture For

  HuREL® Enters Into Cell-Based R&D Collaboration With Sanofi US To Validate
  HuRELhuman™ In Vitro Liver Tissue Co-Culture For Use In Pre-Clinical Drug
                                 Development

PR Newswire

NORTH BRUNSWICK, N.J., Oct. 1, 2013

NORTH BRUNSWICK, N.J., Oct. 1, 2013 /PRNewswire/ -- HuREL Corporation
("Hurel"), a world-leading provider of advanced tissue constructs and
microfluidic cell-based assay platforms for pre-clinical drug development,
today announced that it has entered into a multi-phase Research and
Development collaboration with Sanofi US Services Inc. ("Sanofi US"). Sanofi,
an integrated global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs.

Under terms of the collaboration agreement, Sanofi US will fund a range of
studies designed to evaluate the utility of HuREL's cell-based products and
technologies for pre-clinical drug development. Different aspects of the
collaboration will be carried out in HuREL's laboratories in North Brunswick,
New Jersey, as well as in various Sanofi R&D locations in both the United
States and Europe. HuREL and Sanofi US intend to share the results of their
R&D collaboration through one or more co-authored, peer-reviewed scientific
publications.

"Through collaborating with our network of internal and external partners,
Sanofi R&D focuses on translating the findings of basic research more quickly
and efficiently into meaningful healthcare solutions," said Marc Bonnefoi,
Head of Sanofi's North America R&D Hub. "Our partnership with HuREL is an
opportunity to leverage an innovative new life sciences technology to
accelerate drug development and impact the lives of patients."

The initial phase of the R&D collaboration will aim to validate HuREL's
HuRELhuman^TM 3D liver tissue co-culture for use across an array of
experimental requirements that are typically addressed during the pre-clinical
phase of drug discovery and development. These applications include both
toxicological studies, which probe to predict and potentially improve the
safety of a prospective new medicine before it is prescribed to humans; as
well as studies of drug metabolism and pharmacokinetics, which aim to
understand and predict how the body's innate biochemical mechanisms may
determine a drug's absorption and distribution through different organs, its
molecular breaking down and transformation, and its eventual elimination from
the body.

Subsequent phases of the collaboration are planned to broaden the range of
validated applications, as well as to cover HuREL's HuRELflow^TM microfluidic
assay platform, in which the liquid culture medium containing the molecular
entity under study is recirculated in a microfluidic pathway, analogously to
how the bloodstream recirculates through the various organs of the body.

HuREL CEO Robert Freedman said, "Sanofi anchors its approach to R&D in the
conviction that new life sciences technologies can be of practical value only
when they can translate from the laboratory benchtop all the way to a new
medicine that is demonstrably safe and of novel efficacy in humans, and that
receives regulatory approval. We are honored and thrilled to have such a
company as Sanofi choose to be our R&D collaboration partner. And we are
confident that HuREL's technology constitutes the kind of game-changing
translational tool for which both drug developers and the regulators have been
waiting."

HuREL Corporation's patent-pending HuRELhuman^TM in vitro liver tissue
construct utilizes a proprietary co-culture of primary cryopreserved human
hepatocytes (i.e., actual human liver cells) to deliver highly sensitive and
accurate predictions of the liver-mediated effects of drugs on humans.
Compared to other in vitro methods, HuRELhuman^TM is distinguished not only by
its predictive accuracy and responsiveness, but also by its long endurance
(maintaining its functionality over weeks instead of over the days or hours
typical of most in vitro systems in use today); the stability of the results
it delivers over time; and its ease, convenience, and practicality of use in
industrial laboratory settings. In addition to HuRELhuman^TM, the company
offers companion products HuRELdog^TM and HuRELrat^TM, which enable the
comparison of a drug candidate's test results across human, large-animal and
small-animal species. A future product, the HuRELflow^TM microfluidic assay
platform, is currently in its beta-test phase of development.

About HuREL
HuREL Corporation, situated in North Brunswick, NJ and Beverly Hills, CA, is a
world-leading provider of advanced artificial tissue constructs and
microfluidic cell-based assay platforms that are used by major pharmaceutical
research organizations in pre-clinical drug development, as well as in the
toxicological testing of industrial materials and consumer products. More
information about HuREL can be found at http://hurelcorp.com.

SOURCE HuREL Corporation

Website: http://hurelcorp.com
Contact: For HuREL: Tony Herrling / Raymond Yeung, Brainerd Communicators,
212-986-6667, herrling@braincomm.com / yeung@braincomm.com